Literature DB >> 7542902

Potential activities of androgen metabolizing enzymes in human prostate.

M Krieg1, H Weisser, S Tunn.   

Abstract

The entire androgen metabolism of the human prostate is an integral part of the DHT mediated cellular processes, which eventually give rise to the androgen responsiveness of the prostate. Therefore, the potential activities of various androgen metabolizing enzymes were studied. Moreover, the impact of aging on the androgen metabolism and the inhibition of 5 alpha-reductase by finasteride were studied. In epithelium (E) and stroma (S) of normal (NPR) and hyperplastic human prostate (BPH), for each enzyme being involved in the conversion either of testosterone via DHT, 3 alpha- and 3 beta-diol to the C19O3-triols or from testosterone to androstenedione and vice versa, the amount (Vmax) and Michaelis constant (Km) were determined by Lineweaver-Burk plots. Furthermore, Vmax/Km quotients were calculated, which served as an index for the potential enzyme activity. 17 enzymes showed a mean Vmax/Km > or = 0.10. The top four were the 5 alpha-reductases in E and S of NPR and BPH. Among those, the highest activity was found in E of NPR (1.6 +/- 0.2). Moreover, in E a significant age-dependent decrease of 5 alpha-reductase activity occurred, whereas in stroma rather constant activities were found over the whole age range. Similar age-dependent alterations were found for the cellular DHT levels. Finally, the finasteride inhibition of 5 alpha-reductase (IC50;nM) was stronger in E (35 +/- 17) than in S (126 +/- 15). In conclusion, 5 alpha-reductase is: (a) the outstanding androgen metabolizing enzyme in NPR and BPH; (b) dictating the DHT enrichment in the prostate; (c) under the impact of aging; and (d) preferentially inhibited by finasteride in E.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542902     DOI: 10.1016/0960-0760(95)00085-e

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

1.  Expression in Escherichia Coli, Purification, and Functional Reconstitution of Human Steroid 5α-Reductases.

Authors:  Hwei-Ming Peng; Juan Valentín-Goyco; Sang-Choul Im; Bing Han; Jiayan Liu; Jie Qiao; Richard J Auchus
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

2.  Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life.

Authors:  Joseph John Bianco; Stephen John McPherson; Hong Wang; Gail S Prins; Gail Petuna Risbridger
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

3.  Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.

Authors:  Rui Yang; Yu-Xia Ma; Lin-Feng Chen; Ying Zhou; Zhan-Po Yang; Yan Zhu; Xiao-Ling Du; Jian-Dang Shi; Hong-Shun Ma; Ju Zhang
Journal:  Asian J Androl       Date:  2010-05-17       Impact factor: 3.285

Review 4.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

Review 5.  Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics and pharmacodynamics of finasteride.

Authors:  J F Steiner
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

7.  Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats.

Authors:  Ying Zhou; Xiang-Qian Xiao; Lin-Feng Chen; Rui Yang; Jian-Dang Shi; Xiao-Ling Du; Helmut Klocker; Irwin Park; Chung Lee; Ju Zhang
Journal:  Asian J Androl       Date:  2009-06-01       Impact factor: 3.285

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.